S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

Unicycive Therapeutics Stock Forecast, Price & News

-0.10 (-4.67%)
(As of 12/1/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
215,603 shs
Average Volume
487,375 shs
Market Capitalization
$30.54 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive UNCY News and Ratings via Email

Sign-up to receive the latest news and ratings for Unicycive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Unicycive Therapeutics logo

About Unicycive Therapeutics

Unicycive Therapeutics Inc. is a clinical stage biotechnology company. It involved in developing therapies for patients with kidney disease. The company's lead drug consist Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive Therapeutics Inc. is based in LOS ALTOS, Calif.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales


Pretax Margin




Free Float
Market Cap
$30.54 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.70 out of 5 stars

Medical Sector

923rd out of 1,392 stocks

Pharmaceutical Preparations Industry

436th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Unicycive Therapeutics (NASDAQ:UNCY) Frequently Asked Questions

Is Unicycive Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Unicycive Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Unicycive Therapeutics stock.
View analyst ratings for Unicycive Therapeutics
or view top-rated stocks.

Are investors shorting Unicycive Therapeutics?

Unicycive Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 70,700 shares, a drop of 34.9% from the October 31st total of 108,600 shares. Based on an average trading volume of 168,000 shares, the short-interest ratio is presently 0.4 days. Approximately 0.8% of the shares of the stock are sold short.
View Unicycive Therapeutics' Short Interest

When is Unicycive Therapeutics' next earnings date?

Unicycive Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Unicycive Therapeutics

How were Unicycive Therapeutics' earnings last quarter?

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) announced its earnings results on Thursday, November, 11th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.26.
View Unicycive Therapeutics' earnings history

What price target have analysts set for UNCY?

2 brokerages have issued twelve-month price targets for Unicycive Therapeutics' stock. Their forecasts range from $13.50 to $13.50. On average, they anticipate Unicycive Therapeutics' stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 561.8% from the stock's current price.
View analysts' price targets for Unicycive Therapeutics
or view top-rated stocks among Wall Street analysts.

When did Unicycive Therapeutics IPO?

(UNCY) raised $25 million in an initial public offering on Tuesday, July 13th 2021. The company issued 4,600,000 shares at $5.00-$6.00 per share. Roth Capital Partners acted as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager.

What is Unicycive Therapeutics' stock symbol?

Unicycive Therapeutics trades on the NASDAQ under the ticker symbol "UNCY."

When does Unicycive Therapeutics' lock-up period expire?

Unicycive Therapeutics' lock-up period expires on Monday, January 10th. Unicycive Therapeutics had issued 5,000,000 shares in its IPO on July 13th. The total size of the offering was $25,000,000 based on an initial share price of $5.00. After the expiration of Unicycive Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Unicycive Therapeutics' major shareholders?

Unicycive Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Board of Trustees of The Leland Stanford Junior University (1.71%), Geode Capital Management LLC (0.18%), Two Sigma Investments LP (0.18%), Tandem Capital Management Corp ADV (0.11%) and BlackRock Inc. (0.08%).

Which major investors are buying Unicycive Therapeutics stock?

UNCY stock was purchased by a variety of institutional investors in the last quarter, including Board of Trustees of The Leland Stanford Junior University, Geode Capital Management LLC, Two Sigma Investments LP, Tandem Capital Management Corp ADV, and BlackRock Inc..

How do I buy shares of Unicycive Therapeutics?

Shares of UNCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Unicycive Therapeutics' stock price today?

One share of UNCY stock can currently be purchased for approximately $2.04.

How much money does Unicycive Therapeutics make?

Unicycive Therapeutics has a market capitalization of $30.54 million.

What is Unicycive Therapeutics' official website?

The official website for Unicycive Therapeutics is www.unicycive.com.

Where are Unicycive Therapeutics' headquarters?

Unicycive Therapeutics is headquartered at 5150 EL CAMINO REAL SUITE A-32, LOS ALTOS CA, 94022.

How can I contact Unicycive Therapeutics?

Unicycive Therapeutics' mailing address is 5150 EL CAMINO REAL SUITE A-32, LOS ALTOS CA, 94022. The company can be reached via email at [email protected].

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.